secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0001193125-23-010643
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic receives FDA Rare Pediatric Disease Designation for SYNB1934 in PKU
----------------------------------------------------------------------------

- FDA granted RPDD for SYNB1934, a synthetic biotic candidate for phenylketonuria (PKU).
- Company plans to start Synpheny-3 pivotal Phase 3 study for SYNB1934 in H1 2023.
- Follows similar RPDD for SYNB1353 for homocystinuria (HCU) received in December 2022.
- Designation highlights the urgent need for new PKU treatment options in children.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312523010643/0001193125-23-010643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312523010643/d457598d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-010643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer